Long-Acting Thyroid Stimulator and Exophthalmos
Authors: GERALD BURKE
Journal: Annals of Internal Medicine (1969)

Editorial Notes1 May 1969Long-Acting Thyroid Stimulator and ExophthalmosGERALD BURKE, M.D., C.M., F.A.C.PGERALD BURKE, M.D., C.M., F.A.C.PSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-70-5-1045 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe role of the long-acting thyroid stimulator (LATS) in the development, or progression, or both, of infiltrative ophthalmopathy continues to be the subject of considerable speculation. Because resolution of this putative relationship may have considerable therapeutic import, the evidence for and against such a causal role for LATS bears close scrutiny.The frequency with which LATS has been found on assay of whole serum in Graves' disease has varied markedly (1). However, the thesis that the stimulator is present in all instances of hyperthyroidism of Graves' disease and is therefore a causative factor is supported by the demonstration of LATS...References1. BURKE G: The long-acting thyroid stimulator of Graves' disease. Amer. J. Med. 45: 435, 1968. CrossrefMedlineGoogle Scholar2. CARNEIRODORRINGTONMUNRO LKJDS: Recovery of the long-acting thyroid stimulator from serum of patients with thyrotoxicosis by concentration of immunoglobulin G. Clin. Sci. 31: 215, 1966. MedlineGoogle Scholar3. LIPMANGREENSNYDERNELSONSOLOMON LMDEVJJCDH: Relationship of long-acting thyroid stimulator to the clinical features and course of Graves' disease. Amer. J. Med. 43: 486, 1967. CrossrefMedlineGoogle Scholar4. MCKENZIEMCCULLAGH JMEP: Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease. J. Clin. Endocr. 28: 1177, 1968. CrossrefMedlineGoogle Scholar5. HETZELMASONWANG BSEKHK: Studies of serum long-acting thyroid stimulator (LATS) in relation to exophthalmos after therapy for thyrotoxicosis. Aust. Ann. Med. 17: 307, 1968. MedlineGoogle Scholar6. KRISSPLESHAKOVROSENBLUMHOLDERNESSSHARPUTIGER JPVALMGR: Studies on the pathogenesis of the ophthalmopathy of Graves' disease. J. Clin. Endocr. 27: 582, 1967. CrossrefGoogle Scholar7. BURKE G: Dissociation between thyroid injury and formation of long-acting thyroid stimulator in thyrotoxicosis. Ann. Intern. Med. 67: 349, 1967. LinkGoogle Scholar8. PINCHERALIBERTYMARTINOFENZIGRASSOROVISBASCHIERIDORIA APEGFLLLG: Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. J. Clin. Endocr. 29: 231, 1969. CrossrefGoogle Scholar9. VOLPÉDESBARATS-SCHONBAUMEZRIN RMLC: The effect of thyroid radioablation in Graves' disease with high LATS assays (abstract), in Program of the American Thyroid Association, vol. 44, 1967, p. 77. Google Scholar10. BROWNCOBURNWIGODHISSDOWLING JJWRAJMJT: Adrenal steroid therapy of severe infiltrative ophthalmopathy of Graves' disease. Amer. J. Med. 34: 786, 1963. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Michael Reese Hospital and Medical Center Chicago, Ill. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThe treatment of thyrotoxicosis by radioiodineLymphocytic Thyroiditis and ThyrotoxicosisLATS AND THYROTOXICOSISSEYMOUR HERSCHBERG, M.D. 1 May 1969Volume 70, Issue 5Page: 1045-1046KeywordsHyperthyroidismThyroid Issue Published: 1 May 1969 PDF DownloadLoading ...